A study conducted at the humanities and medicine departments at Penn State College of Medicine in Hershey, Pennsylvania, found that there's never an ideal time to talk to cancer patients about end-of-life decisions, and most patients are not too disturbed by these discussions.
For a small group of advanced cancer patients, using an online tool for learning about end-of-life medical decisions and developing an advance directive document did not lead to psychological distress, according to a new study.
“One thing we noticed is that many patients with advanced cancer had not had these conversations,” said lead author Dr. Michael J. Green of the humanities and medicine departments at Penn State College of Medicine in Hershey, Pennsylvania.
“When we talked to the oncologists about it, a response we heard again and again is, ‘it’s not appropriate at this time, it’s going to make them anxious, take away their hope’,” Green told Reuters Health.
Read the complete report on Reuters: http://reut.rs/1KiT9sK
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More